Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › burosumab

burosumab

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of burosumab

7 trials tracked of burosumab: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 366 citations.

7Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 4
  1. Phase 3 Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH Completed · 366 cited
  2. Phase 3 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Completed · 340 cited
  3. Phase 3 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Completed · 17 cited
  4. Phase 2 Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Completed
  5. Phase 2 Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Completed
  6. Phase 2 Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Completed
Show 1 more trials
  1. Phase 2 Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia
Pediatrics FDA Approval
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia FDA approves new drug Crysvita for rare bone diseases in children and adults
FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) in patients 6 months and older and for tumor-induced osteomalacia (TIO…
The FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).
FDA Apr 29, 2026
Burosumab improves phosphate levels in 12 children and adults with fibrous dysplasia over 48 weeks
Pediatrics Phase II
Burosumab improves phosphate levels in 12 children and adults with fibrous dysplasia over 48 weeks Burosumab Restores Phosphate Balance in Rare Bone Disease
This Phase 2 trial enrolled 12 participants (7 children, 5 adults) with fibrous dysplasia to assess burosumab.
A drug already used for rare phosphate disorders may finally offer real relief for people with fibrous dysplasia, a painful bone condition t…
Apr 27, 2026
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals
Drug Pipeline
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals Burosumab Patients May Skip Fasting Before Blood Tests
This abstract describes a substudy of Phase 3 clinical trials evaluating burosumab in adults and children with X-linked hypophosphatemia.
Imagine rushing your child to a morning blood draw, stomach empty, hungry and fussy—only to find out the results might not even require fast…
Apr 24, 2026
Review examines current endocrine causes of secondary osteoporosis and clinical management approaches
Diabetes & Endocrinology Sys. Review
Review examines current endocrine causes of secondary osteoporosis and clinical management approaches Why Normal Hormones Can Still Break Bones
This review synthesizes evidence on endocrine-related secondary osteoporosis across conditions like hypercortisolism and male hypogonadism.
You might think strong bones only come from aging women or older men.
Frontiers Apr 21, 2026
Burosumab improved clinical and biochemical outcomes in patients with tumor-induced osteomalacia
Diabetes & Endocrinology Meta-analysis
Burosumab improved clinical and biochemical outcomes in patients with tumor-induced osteomalacia Can a new drug help patients with tumor-induced bone loss before surgery?
This hybrid study, combining a clinical survey with a systematic review, evaluated burosumab in patients with tumor-induced osteomalacia.
A new drug helps patients with tumor-induced bone loss improve health and blood chemistry while waiting for surgery or if surgery isn't poss…
Frontiers Apr 14, 2026